Targets › GREM1
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jun 2027.
Cytokine that may play an important role during carcinogenesis and metanephric kidney organogenesis, as a BMP antagonist required for early limb outgrowth and patterning in maintaining the FGF4-SHH feedback loop. Down-regulates the BMP4 signaling in a dose-dependent manner (By similarity). (UniProt, O60565)
Open in Phaseline: the race on GREM1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Transcenta Therapeutics (Hangzhou) | TST003 humanized anti-GREM1 monoclonal antibody | GREM1 | Phase 1 | Locally Advanced Solid Tumor | Jun 2027 |
Locally Advanced Solid Tumor (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.